Ruxolitinib suppresses liver fibrosis progression and accelerates fibrosis reversal via selectively targeting Janus kinase 1/2.

Zhenghui SongXinhui LiuWan ZhangYue LuoHua XiaoYun LiuGuanqi DaiJian HongAimin Li

Published in: Journal of translational medicine (2022)

JAK1/2 regulates the function of HSCs and plays an essential role in liver fibrosis and HCC development. Its inhibitor, Ruxolitinib, may be an effective drug for preventing and treating liver fibrosis.

Keyphrases

liver fibrosis
signaling pathway
cancer therapy
emergency department
protein kinase
drug delivery